NHNKY

Nihon Kohden Corporation [NHNKY] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

NHNKY Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

NHNKY has more than 6 years of cash runway (73 months)

Earnings are expected to fall -100% next year

Profit margins (0.08%) are lower than the previous year (0.11%)

Top 10 Correlated ETFs

NHNKY

Top 10 Correlated Stocks

NHNKY

In the News

NHNKY Financial details

Company Rating

Buy

Market Cap

2.31B

Income

15.38B

Revenue

201.61B

Book val./share

956.59

Cash/share

259.4

Dividend

Dividend %

Employees

5.64K

Optionable

Shortable

Yes

Earnings

31 Dec 2022

P/E

21.11

Forward P/E

PEG

-13.98

P/S

1.61

P/B

2.01

P/C

0.05

P/FCF

-92.96

Quick Ratio

1.04

Current Ratio

3.93

Debt / Equity

0.28

LT Debt / Equity

EPS (TTM)

90.94

EPS next Y

EPS next Q

EPS this Y

29.08%

EPS next Y

EPS next 5Y

EPS last 5Y

20.93%

Revenue last 5Y

3.32%

Revenue Q/Q

0.44%

EPS Q/Q

-93.45%

SMA20

-0.29%

SMA50

5.96%

SMA100

16.57%

Inst Own

Inst Trans

ROA

ROE

10%

ROC

0.13%

Gross Margin

51%

Oper. Margin

11%

Profit Margin

Payout

37%

Shs Outstand

168.25M

Shs Float

168.01M

Target Price

52W Range

9.95-14.56

52W High

-0.71%

52W Low

+54.44%

RSI

49.94

Rel Volume

0.89

Avg Volume

1.82K

Volume

1.61K

Perf Week

-0.22%

Perf Month

-0.14%

Perf Quarter

19.42%

Perf Half Y

19.93%

Beta

-0.071566

Volatility

0.1%, 0.21%

Prev Close

1.13%

Price

13.9

Change

1.13%

NHNKY Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-03-31

Metric	2018-03-31	2019-03-31	2020-03-31	2021-03-31	2022-03-31
Revenue per share	1.02K	1.05K	1.09K	1.17K	1.21K
Net income per share	53.46	65.71	57.86	107.1	138.25
Operating cash flow per share	63.32	57.65	54.12	81.87	151.6
Free cash flow per share	43.96	38.57	33.03	62	134.3
Cash per share	184.48	204.4	211.19	261.9	359.41
Book value per share	638.6	681.61	715.01	815.96	922.51
Tangible book value per share	608.94	654.82	690.65	802.29	900.47
Share holders equity per share	638.6	681.61	715.01	815.96	922.51
Interest debt per share	3.18	2.61	2.41	2.42	2.18
Market cap	263.79B	281.82B	360.99B	265.65B	247.45B
Enterprise value	247.71B	263.45B	340.43B	235.44B	218.89B
P/E ratio	28.82	25.18	36.63	14.56	10.56
Price to sales ratio	1.51	1.58	1.95	1.33	1.21
POCF ratio	24.33	28.7	39.17	19.05	9.63
PFCF ratio	35.04	42.9	64.17	25.15	10.87
P/B Ratio	2.41	2.43	2.96	1.91	1.58
PTB ratio	2.41	2.43	2.96	1.91	1.58
EV to sales	1.42	1.47	1.84	1.18	1.07
Enterprise value over EBITDA	14.18	13.71	18.24	7.15	5.74
EV to operating cash flow	22.85	26.83	36.93	16.88	8.52
EV to free cash flow	32.91	40.1	60.51	22.29	9.62
Earnings yield	0.03	0.04	0.03	0.07	0.09
Free cash flow yield	0.03	0.02	0.02	0.04	0.09
Debt to equity	0.44	0.46	0.38	0.39	0.34
Debt to assets	0.31	0.32	0.27	0.28	0.26
Net debt to EBITDA	-0.92	-0.96	-1.1	-0.92	-0.75
Current ratio	2.79	2.73	3.2	3.09	3.38
Interest coverage	537.67	1.67K	1.55K	3.39K	2.82K
Income quality	1.18	0.88	0.66	0.51	0.75
Dividend Yield	0.01	0.01	0.01	0.01	0.02
Payout ratio	0.33	0.27	0.3	0.16	0.21
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.03	0.03	0.02	0.01	0.02
Capex to operating cash flow	-0.31	-0.33	-0.39	-0.24	-0.11
Capex to revenue	-0.02	-0.02	-0.02	-0.02	-0.01
Capex to depreciation	-0.95	-0.88	-0.96	-0.74	-0.84
Stock based compensation to revenue	0	0	0	0	0
Graham number	876.43	1K	964.79	1.4K	1.69K
ROIC	0.1	0.11	0.11	0.17	0.17
Return on tangible assets	0.06	0.07	0.06	0.1	0.11
Graham Net	-31.84	-26.55	26.88	58.74	184.56
Working capital	80B	83.87B	88.7B	105.53B	121.07B
Tangible asset value	104.27B	111.52B	117.62B	136.65B	152.64B
Net current asset value	76.01B	78.58B	83.01B	102.09B	118.05B
Invested capital	0	0	0	0	0
Average receivables	0	0	0	0	0
Average payables	31.19B	31.25B	28.2B	24.08B	24.23B
Average inventory	22.87B	25.85B	28.92B	34.07B	43.63B
Days sales outstanding	0	0	0	0	0
Days payables outstanding	119.07	128.38	90.62	91.4	91.38
Days of inventory on hand	92.15	112.46	111.57	145.58	183.81
Receivables turnover	0	0	0	0	0
Payables turnover	3.07	2.84	4.03	3.99	3.99
Inventory turnover	3.96	3.25	3.27	2.51	1.99
ROE	0.08	0.1	0.08	0.13	0.15
Capex per share	-19.36	-19.08	-21.09	-19.87	-17.31

Quarterly Fundamentals Overview

Last date of statement is 2022-12-31 for Q3

Metric	2021-12-31	2022-03-31	2022-06-30	2022-09-30	2022-12-31
Revenue per share	269.01	335.57	263.19	296.55	297.87
Net income per share	27.16	38.37	21.83	28.85	1.89
Operating cash flow per share	7.58	57.68	-8.85	-12.01	-32.16
Free cash flow per share	2.89	51.77	-17.98	-17.67	-37.26
Cash per share	302.8	358.36	323.56	311.11	259.4
Book value per share	883.32	919.82	928.18	963.61	956.59
Tangible book value per share	862.09	897.84	904.09	938.14	931.12
Share holders equity per share	883.32	919.82	928.18	963.61	956.59
Interest debt per share	2.06	2.15	1.93	1.95	2.57
Market cap	270.29B	248.18B	228.82B	259.39B	264.56B
Enterprise value	242.16B	219.61B	192.61B	230.28B	224.26B
P/E ratio	14.64	9.51	15.55	13.34	207.33
Price to sales ratio	5.91	4.35	5.16	5.19	5.27
POCF ratio	209.69	25.31	-153.37	-128.16	-48.8
PFCF ratio	549.36	28.2	-75.52	-87.1	-42.12
P/B Ratio	1.8	1.59	1.46	1.6	1.64
PTB ratio	1.8	1.59	1.46	1.6	1.64
EV to sales	5.29	3.85	4.34	4.61	4.47
Enterprise value over EBITDA	31.71	20.05	30.52	27.25	126.42
EV to operating cash flow	187.86	22.4	-129.1	-113.77	-41.37
EV to free cash flow	492.19	24.95	-63.57	-77.33	-35.71
Earnings yield	0.02	0.03	0.02	0.02	0
Free cash flow yield	0	0.04	-0.01	-0.01	-0.02
Debt to equity	0.28	0.34	0.3	0.29	0.28
Debt to assets	0.22	0.26	0.23	0.22	0.22
Net debt to EBITDA	-3.68	-2.61	-5.74	-3.45	-22.71
Current ratio	4.01	3.38	3.73	3.83	3.93
Interest coverage	6.68K	1.1K	5.49K	2.52K	824
Income quality	0.28	1.02	-0.27	-0.27	-5.92
Dividend Yield	0.01	0	0.02	0	0.01
Payout ratio	0.35	0	1.08	0.01	5.26
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0.02	0.02	0.02	0.02	0.02
Capex to operating cash flow	-0.62	-0.1	1.03	0.47	0.16
Capex to revenue	-0.02	-0.02	-0.03	-0.02	-0.02
Capex to depreciation	-0.84	-1.03	-1.86	-1.08	-0.91
Stock based compensation to revenue	0	0	0	0	0
Graham number	734.67	891.17	675.15	790.82	201.83
ROIC	0.04	0.04	0.03	0.04	0
Return on tangible assets	0.02	0.03	0.02	0.02	0
Graham Net	189.93	184.02	201.82	204.75	172.83
Working capital	115.26B	121.07B	119.24B	124.31B	122.84B
Tangible asset value	146.56B	152.64B	152.39B	158.13B	156.95B
Net current asset value	111.8B	118.05B	116.24B	121.34B	119.97B
Invested capital	0	0	0	0	0
Average receivables	0	0	0	0	0
Average payables	20.02B	22.62B	22.87B	21.51B	22.15B
Average inventory	42.65B	46.8B	50.33B	55.09B	59.12B
Days sales outstanding	0	0	0	0	0
Days payables outstanding	90.65	79.7	86.55	79.36	85.01
Days of inventory on hand	193.56	160.31	208.67	215.27	223.47
Receivables turnover	0	0	0	0	0
Payables turnover	0.99	1.13	1.04	1.13	1.06
Inventory turnover	0.46	0.56	0.43	0.42	0.4
ROE	0.03	0.04	0.02	0.03	0
Capex per share	-4.69	-5.91	-9.12	-5.66	-5.1

NHNKY Frequently Asked Questions

What is Nihon Kohden Corporation stock symbol ?

Nihon Kohden Corporation is a JP stock and trading under the symbol NHNKY

What is Nihon Kohden Corporation stock quote today ?

Nihon Kohden Corporation stock price is $13.9 today.

Is Nihon Kohden Corporation stock public?

Yes, Nihon Kohden Corporation is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.82K
Market Capitalization 2.31B
Employee 5.64K
CEO Mr. Hirokazu Ogino
Headquarters Tokyo,JP
IPO Date 2013-09-27
Website https://www.nihonkohden.com

Nihon Kohden Corporation engages in research and development, production, sale, repair, and maintenance of medical electronic equipment in Japan, Americas, Europe, rest of Asia, and internationally. The company offers physiological measuring equipment, including electroencephalographs, electrocardiographs, evoked potential and electromyogram measuring instruments, and polygraphs for cath labs, as well as diagnostic information systems and related consumables, such as recording papers, electrodes and catheters, and maintenance services. It also provides patient monitors systems comprising central monitors, bedside monitors, wireless monitors, remote access software, and other equipment; and clinical information systems and related consumables, such as electrodes and sensors. In addition, the company offers treatment equipment, which include defibrillators, automated external defibrillators (AED), ventilators, pacemakers, anesthesia machines, cochlear implants, and related consumables and services, which include AED pads and batteries; and other medical equipment, including hematology and clinical chemistry analyzers, ultrasound diagnostic equipment, and equipment for research and others, as well as consumables, including test reagents, and installation and maintenance services. Additionally, it engages in insurance brokerage and technology licensing business. The company was incorporated in 1951 and is headquartered in Tokyo, Japan.